Accenture, Synopsys and United Therapeutics lead midday stock moves
A mix of earnings beats, legal rulings and strategic announcements is driving sharp midday moves across U.S. equities. Accenture, Synopsys and United Therapeutics are among the biggest gainers, while Sigma Lithium and Corteva are posting steep declines.
Highlights
- Accenture shares surge 18% after reporting fiscal Q4 revenue of $18.7 billion and earnings of $3.29 per share, both topping estimates.
- Synopsys jumps over 8% post-investor day as it raises 2027 revenue targets to $11.1–$11.2 billion, unveils a strategic OpenAI partnership, and outpaces analyst expectations.
- United Therapeutics climbs 6% after a Delaware federal court rules in its favor against Liquidia, prompting BTIG's upgrade and clearing growth path through 2027.
Corporate updates drive trading moves
As reported by CNBC, Accenture shares soar 18% after the professional services company reports fiscal fourth-quarter revenue of $18.7 billion, above its guidance range of $17.8 billion to $18.4 billion and ahead of FactSet's $18.3 billion consensus estimate. Earnings of $3.29 per share also top expectations.Synopsys jumps more than 8% after its investor day lays out a growth strategy and long-term targets. The software company says it expects 2027 revenue growth of 15%, reaching $11.1 billion to $11.2 billion, above the $10.82 billion analysts expected, according to FactSet, and it also announces a strategic partnership with OpenAI.
McCormick posts stronger-than-expected third-quarter results, with adjusted earnings of 86 cents per share beating the 76 cents expected by analysts polled by FactSet and revenue of $2.02 billion topping the $1.98 billion estimate. Its shares still fall more than 2%, while Unilever, which is acquiring the company, also drops more than 2%.
McKesson rises 4% after reaffirming fiscal 2027 earnings per share guidance and extending its partnership with CVS Health through June 2032 to distribute pharmaceuticals to mail order, specialty and retail pharmacies, and distribution centers. The company is due to report fiscal second-quarter results on Nov. 4.
Vicor surges almost 10% after raising third-quarter revenue growth guidance to more than 30% from previous guidance of at least 20%. The company links the improved outlook to increased royalties from its previously announced first non-exclusive license to Vertical Power Delivery.
Legal decisions and deal activity hit laggards
United Therapeutics climbs 6% after a Delaware federal court rules Wednesday that Liquidia's lung treatment infringes a patent held by United Therapeutics. BTIG upgrades United Therapeutics to buy after the decision, saying the legal outcome likely clears a path to resumed growth through 2027, while downgrading Liquidia to neutral.Liquidia tumbles 15% on the court ruling, with BTIG saying the decision is a negative outcome because the company's ability to market Yutrepia is expected to be restricted. The move adds to a session in which legal and regulatory developments are weighing heavily on several names.
Constellation Energy gains nearly 3% after announcing a 20-year deal with Amazon to support generating capacity expansion at a Maryland nuclear power plant. In contrast, Sigma Lithium slides 16% after temporarily suspending all mining and industrial production Wednesday following a 15-day delay by Brazil's Federal Court of Appeals in reviewing the company's legal defense.
Acuity Brands drops nearly 4% after forward guidance for low- to mid-teens net sales growth at Acuity Intelligent Spaces comes in a bit below Wall Street consensus, according to StreetAccount. BJ's Restaurants adds about 5% after Mizuho upgrades the stock to outperform and raises its price target to $76 per share, citing stronger same-store sales checks and potential estimate revisions through 2027.
Corteva says it formally spins off its Vylor seed and genetic business, leaving the company as a pure-play global crop protection group. After the separation, the remainder of Corteva plunges 84%, following an appeals court decision denying California a temporary restraining order and preliminary injunction that sought to delay the spin.
Accenture’s fiscal fourth-quarter results and outlook drove a record-setting surge in the stock, as the company beat estimates on revenue and earnings and issued fiscal 2027 guidance calling for 3%–6% growth. Our earlier coverage also highlighted how Accenture has been ramping up AI training and client adoption work to counter investor concerns about AI disruption in consulting, while supporting profitability through cost reductions and returning cash to shareholders.